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Background: It is currently unknown,whether and towhat extent sensitive cardiac troponin (s-cTn) allows short-
ening of the time required for safe rule-out and rule-in of acute myocardial infarction (AMI).
Methods:We aimed to develop and validate early rule-out and rule-in algorithms for AMI using a thoroughly-
examined and commonly used s-cTnI assay in a prospective multicenter study including 2173 patients present-
ing to the emergency department with suspected AMI. S-cTnI was measured in a blinded fashion at 0 h, 1 h, and
2 h. The ﬁnal diagnosis was centrally adjudicated by two independent cardiologists. In the derivation cohort
(n = 1496), we developed 1 h- and 2 h-algorithms assigning patients to “rule-out”, “rule-in”, or “observe”.
The algorithms were then prospectively validated in the validation cohort (n = 677).
Results: AMI was the adjudicated diagnosis in 17% of patients. After applying the s-cTnI 1 h-algorithm developed in
the derivation cohort to the validation cohort, 65% of patients were classiﬁed as “rule-out”, 12% as “rule-in”, and 23%
to “observe”. The negative predictive value for AMI in the “rule-out” group was 98.6% (95% CI, 96.9–99.5), the pos-
itive predictive value for AMI in the “rule-in” group 76.3% (95% CI, 65.4–85.1). Overall, 30-daymortality was 0.2% in
the “rule-out” group, 1.0% in the “observe” group, and 3.0% in the “rule-in” group. Similar results were obtained for
the 2 h-algorithm.
Conclusion:When used in conjunction with other clinical information including the ECG, a simple algorithm incor-
porating s-cTnI values at presentation and after 1 h (or 2 h)will allow safe rule-out and accurate rule-in of AMI in the
majority of patients.© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients presenting with symptoms suggestive of acute myocardial
infarction (AMI) account for about 5–10% of emergency department
(ED) presentations and up to 25% of medical hospital admissions in
Europe and theUnited States [1–3]. Rapid identiﬁcation of AMI is criticalcTn, cardiac Troponin; ECG,
gh-sensitivity cardiac Troponin;
value; s-cTn, sensitive cardiac
ability and freedom from bias of
gy, University Hospital Basel,
.
land Ltd. This is an open access articlfor the initiation of effective evidence-based medical treatment and
management [4–5]. “Rule-out” of AMI is of major importance as about
80% of patients with suspected AMIwill be found to have a ﬁnal diagno-
sis other than AMI [6-9]. Delays in “rule-in” of AMI increase mortality
and morbidity, whereas delayed “rule-out” of AMI leads to prolonged
assessments, unnecessary investigation, increases patient anxiety, in-
terferences with alternative diagnosis and expensive overcrowding in
the ED [1].
Detailed patient history and physical examination, the 12-lead
electrocardiogram (ECG), and cardiac troponin (cTn) are the corner-
stones for the early diagnosis of AMI. Sensitive and high-sensitivity
cTn (hs-cTn) assays, which allow measurement of even low cTn con-
centrations with high precision, have been shown to provide higher di-
agnostic accuracy in the diagnosis of AMI at presentation as compared
to conventional assays [8, 10-11]. Accordingly, it has been suggestede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the dilemma of waiting in the ED for the second cTn draw after 6 h.
However, it is currently unknown whether and to what extent a short-
ening of the time interval to the second sample is feasible and safe.
Recently, in a pilot study a 1 h-algorithm using hs-cTnT has been
shown to provide excellent results [11]. This algorithm is based on
two concepts: First, the interpretation of hs-cTn as a quantitative vari-
able where the proportion of patients indeed suffering from AMI con-
tinuously increases with increasing hs-cTn values [ 11, 14-16]. Second,
early absolute concentration changes within 1 h or 2 h can be used as
reliable surrogates for values at 3 h or 6 h and therefore provide incre-
mental value on top of the hs-cTn level at presentation [11,15,16].
Most experts, however, remain skeptical and require additional studies
before considering such an algorithm for use in routine clinical care. In
addition, due to poor harmonization among cTn assays, these ﬁnding
can't automatically be extrapolated to other cTn assays, even less
for cTn assays that do not meet criteria for “high-sensitivity” [14]. As
themajority of institutionsworld-wide use sensitive, but not hs-cTn as-
says, we performed a multicenter study to derive and validate 1 h- and
2 h-algorithms for rule-out and rule-in of AMI using a thoroughly-
examined and commonly used sensitive cTnI assay [8,10,12-23].
2. Methods
2.1. Study design and population
Advantageous Predictors of Acute Coronary Syndrome Evaluation
(APACE) is an open prospective multicenter study designed to advance
the early diagnosis of AMI [10,11,14-16]. From April 2006 to June 2013,
2378 consecutive patients older than 18 years presenting to the EDwith
symptoms suggestive of AMI with an onset or peak within the last 12 h
were recruited, after written informed consent was obtained.
Patients with terminal kidney failure requiring regular dialysis were
excluded. For this analysis patients were also excluded if A) sensitive
cTnI values were not available at either 0 h or 1 h (for 1 h-algorithm),
or 0 h or 2 h (for 2 h-algorithm) or B) patients had a ﬁnal diagnosis of
ST-elevation AMI (n = 99) as biomarkers are considered of limited
value in these or C) the ﬁnal diagnosis remained unclear after adjudica-
tion and at least one hs-cTnT level was elevated (possibly indicating
presence of AMI) (n = 89).
Informed consent was obtained from each patient. The study
protocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a priori approval by the institution's human
research committee. The authors designed the study, gathered and
analyzed the data, vouch for the data and analysis, wrote the paper,
and decided to publish.
2.2. Routine clinical assessment
All patients underwent a clinical assessment that included medical
history, physical examination, 12-lead ECG, continuous ECGmonitoring,
pulse oximetry, standard blood test, and chest radiography. Levels of
cTn were measured at presentation and serially thereafter as long as
clinically indicated. Timing and treatment of patientswere left to discre-
tion of the attending physician.
2.3. Adjudicated ﬁnal diagnosis
Adjudication of the ﬁnal diagnosis was performed centrally at
the laboratory for all patients using also levels of hs-cTnT in order to
take advantage of the higher sensitivity and higher overall diagnostic
accuracy offered by hs-cTn assays [11,15]. This allows the additional de-
tection of small AMIs. Two independent cardiologists reviewed all avail-
able medical records pertaining to the patient from the time of ED
presentation to a 90-day follow-up or longer (patient history, physical
examination, results of laboratory testing, radiologic testing, ECG,echocardiography, cardiac exercise test, lesion severity andmorphology
in coronary angiography). In situations of disagreement about the
diagnosis, cases were reviewed and adjudicated in conjunction with a
third cardiologist.
AMI was deﬁned and cTn levels interpreted as recommended in
current guidelines [4,5]. In brief, AMIwas diagnosedwhen therewas ev-
idence of myocardial necrosis in association with a clinical setting con-
sistent with myocardial ischemia. Late samples of cTn were available
for all adjudicated patients. Myocardial necrosis was diagnosed by at
least one cTn value above the 99th percentile together with a signiﬁcant
rise and/or fall [5,11,15].
2.4. Use of hs-cTnT for adjudication of ﬁnal diagnoses
In order to identify additional patients with small AMIs that were
missed by the adjudication using the less sensitive conventional cTn as-
says a second adjudication using hs-cTnTwas performed in all non-AMI
patients according to the ﬁrst adjudication. For hs-cTnT the 99th per-
centile (14 ng/L) was used as cut-off for myocardial necrosis [24,25].
Absolute changes in hs-cTnT were used to determine signiﬁcant
changes based on the diagnostic superiority of absolute over relative
changes [16,26]. Based on studies of the biological variation of cTn [27,
28] as well as on data from previous chest pain cohort studies [8,29], a
signiﬁcant absolute change was deﬁned as a rise or fall of at least
10 ng/L within 6 h. In patients, in whom a 6 hour hs-cTnT level was
not available, changes were assessed at earlier time points. In an as-
sumption of linearity, an absolute change of 6 ng/L within 3 h, 4 ng/L
within 2 h or 2 ng/L within 1 hwas considered. However, it is important
to highlight that if discordant ﬁndings occurred, the longest time inter-
val available was required to fulﬁll the change criteria.
2.5. Assumption of linearity of absolute changes within the ﬁrst hours
The assumption of linearity of absolute changes within the ﬁrst
hours is based on unpublished internal data as well as recent data
from Ola Hammarsten et al. showing a near-linear increase in levels
of cTn with increasing time from symptom onset in their NSTEMI
cohort [30].
2.6. Measurement of sensitive cTnI and hs-cTnT
The measurement of sensitive cTnI and hs-cTnT is described in the
online-only Data Supplement.
2.7. Statistical analysis
The algorithms for use of sensitive cTnI were developed in all
patients with a complete dataset available in October 2013 (derivation
cohort), allowing for adjudication of the ﬁnal diagnosis. The algorithms
incorporate sensitive cTnI levels at presentation and after a pre-deﬁned
time interval (1 h or 2 h) and absolute s-cTnI changes [11,15,16]. For
“rule-out” of AMI, we selected receiver-operating characteristics curve
(ROC) derived thresholds, allowing for optimal sensitivity of at least
98% and negative predictive value (NPV) of 99%. This approach allowed
forminimizing the number of false negative tests as thesemay have ad-
verse outcome. For “rule-in” of AMI, we obtained cut-off levels by on a
classiﬁcation and regression tree (CART) analysis searching for optimal
speciﬁcity and positive predictive value (PPV). The different approach
for rule-in was chosen because the CART-analysis optimizes as decision
tree for a yes/no-variable. This data-driven approach was chosen in
order to reﬂect a real-life scenario of patients presentingwith suspected
AMI and did not rely on theoretical assumptions regarding CV.
The algorithmdeveloped in the derivation cohortwas then validated
in all additional patients with complete data becoming available in
February 2014. Data are expressed as medians ± interquartile range
(IQR) for continuous variables, and for categorical variables as numbers
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Whitney-U test, and categorical variables using the Pearson chi-square
test. Mortality at 30-days and one year of follow-up according to the
classiﬁcation provided by the algorithms was plotted in Kaplan–Meier
curves, and the log-rank test was used to assess differences in survival
between groups. For survival analysis, we analyzed the derivation co-
hort and the validation cohort combined. All hypothesis testing was
two-tailed and p-value of less than 0.05 was considered statistically sig-
niﬁcant. All statistical analyseswere performed using SPSS forWindows
21.0 (SPSS Inc, Chicago, IL) and MedCalc 9.6.4.0 (MedCalc software,
Mariakerke, Belgium).Fig. 1. Prevalence of acutemyocardial infarction (AMI) according to absolute levels of sen-
sitive cTnI at presentation and after one and two hours (h). Five categories are displayed,
with four pre-deﬁned level thresholds corresponding to the assay lower limit of detection3. Results
Overall, 2173 patients were available for this analysis (Table 1). The
adjudicated ﬁnal diagnosis was AMI in 17% (n = 369), unstable angina
in 10% (n = 225), cardiac symptoms of origin other than coronary
artery disease (CAD) in 15% (n = 328), non- cardiac symptoms in 53%
(n = 1143) and symptoms of unknown origin in 5% (n = 108).of 6 ng/L, 10 ng/L (representing the optimal rule-out cutoff observed for the 1 h- and 2 h-
algorithm), 40 ng/L (as deﬁned as the assay's 99th percentile) and 100 ng/L (empirically
selected). n = number of patients with AMI corresponding to categories.3.1. Prevalence of AMI according to the level of sensitive cTnI
Of all patients, 19% (n = 411) had sensitive cTnI baseline levels
above the 99th percentile of healthy individuals (40 ng/L). If the s-
cTnI assaywas used to detect AMI, and a cut point of the 99th percentile
at baseline was used as single criteria, the sensitivity was 71.7% (95% CI
66.8–76.2%), the NPV 94.1% (95% CI 92.9–95.1%), the speciﬁcity 91.8%
(95% CI 90.5–93.0%) and the PPV 64.1% (95% CI 59.3–68.7%). Prevalence
of AMI showed a near-linear increase with increasing baseline levels of
sensitive cTnI (Fig. 1).Table 1
Baseline characteristics of patients.
All patients 1 h-algorithm 2 h-algorithm p-Value
n = 2173 n = 2053 n = 1659
Age (y), median (IQR) 62 (50–74) 62 (50–74) 62 (49–73) 0.6
Male sex 1490 (69) 1407 (69) 1149 (69) 0.6
Risk factor
Hypertension 1340 (62) 1259 (61) 1031 (62) 0.6
Hypercholesterolemia 1102 (51) 1044 (51) 856 (52) 0.7
Diabetes 385 (18) 371 (18) 294 (18) 0.8
Current smoker 545 (25) 509 (25) 428 (26) 0.5
Former smoker 819 (38) 774 (37) 625 (38) 1.0
History
Coronary artery
heart
disease
761 (35) 716 (35) 586 (35) 0.8
Previous MI 526 (24) 493 (24) 399 (24) 1.0
Previous PCI 540 (25) 506 (25) 421 (25) 0.6
Previous bypass
surgery
200 (9) 192 (9) 148 (9) 0.7
Peripheral artery
disease
131 (6) 120 (6) 102 (6) 0.7
Previous stroke 119 (6) 113 (6) 93 (6) 0.9
eGFR (mL/min),
median (IQR)
85 (70–102) 85 (69–101) 86 (70–102) 0.6
ECG ﬁndings
LBBB 61 (3) 60 (3) 43 (3) 0.6
ST segment elevation 40 (2) 36 (2) 29 (2) 1.0
ST segment
depression
250 (12) 239 (12) 167 (10) 0.1
T-wave-inversion 272 (13) 257 (13) 196 (12) 0.5
Final diagnosis of AMI 369 (17) 351 (17) 260 (16) 0.2
GRACE score 1.0,
median (IQR)
95 (68–126) 95 (68–128) 94 (67–126) 0.9
IQR = interquartile ranges, y = years, MI = myocardial infarction, PCI = percutaneous
coronary intervention, ECG= electrocardiogram, LBBB = left bundle branch block.
Data are presented as numbers (percentage) unless otherwise speciﬁed.3.2. Early and late presenters
Overall, 41.5% of patients (n = 901) presented early deﬁned as an
onset of chest pain ≤3 h, and 58.5% (n = 1272) presented with more
than 3 h after chest pain onset.
3.3. Derivation of the algorithms for the diagnosis of AMI
Two algorithms incorporating levels of sensitive cTnI at presenta-
tion, after 1 or 2 h as well as corresponding absolute delta values were
developed in the derivation cohort (overall, n=1496; Table 2 in the on-
line supplement).
For “rule-out” of AMI with the 1 h-algorithm, we found an optimal
threshold value of 10 ng/L for sensitive cTnI either at presentation or
after 1 h, with an absolute Delta change of less than 4 ng/L within 1 h.
These criteria selected 40% of patients and achieved a sensitivity of
98.9% (95% CI, 96.7–99.8%) and NPV of 99.5% (95% CI, 98.5–99.9%)
(Fig. 2A). A similar algorithmwas derived for the second measurement
at 2 h (Fig. 2C).
For “rule-in” of AMI with the 1 h-algorithm, the optimal thresholds
were either a level of at least 166 ng/L or an absolute delta value of
30 ng/L. These criteria selected 16% of all patients and achieved a spec-
iﬁcity of 96.4 (95%CI, 95.2–97.4%) andPPV of 81.5% (95% CI, 75.8–86.4%)
(Fig. 2A). A similar algorithmwas derived for the second measurement
at 2 h (Fig. 2C).
3.4. Validation of the algorithms for the diagnosis of AMI
These algorithms were tested in a validation sample of 677 patients
(n = 649 for 1 h-algorithm, n = 549 for 2 h-algorithm). After applying
the sensitive cTnI algorithm derived in the derivation cohort to the val-
idation cohort, 65% of patients could be classiﬁed as “rule-out”with the
1 h-algorithmwith a sensitivity of 93.3% (95%CI 85.9–97.5%) andNPV of
98.6% (95% CI 96.9–99.5%). 80 patients (12%) could be classiﬁed as
“rule-in” with a speciﬁcity of 96.6% (95% CI 94.7–98.0%) and PPV of
76.3% (95% CI 65.4–85.1%) for diagnosis of AMI. In the remaining 23%
of patients classiﬁed as ‘observational zone’, the prevalence of AMI
was 15% (Fig. 2).
Characteristics of patients falsely ruled-out for AMI (overall, deriva-
tion and validation cohort, n = 12) are shown in Table 3. Most of
these patients had either ECG changes indicative of AMI or a history
Derivation n=1404 
0h/1h cTnI<10ng/L 
and  <4ng/L Others
0h cTnI 166ng/L 
or 30ng/L 
Sensitivity 98.9% 
NPV 99.5% 
AMI n=3 
Rule-out 
n=561 (40%) 
Observational zone
n=621 (44%) 
Rule-in 
n=222 (16%) 
Specificity 96.4% 
PPV 81.6% 
AMI n=181 
Prevalence of AMI 
12.6% (n=78) 
A = 1h Derivation 
Validation n=649 
0h/1h cTnI<10ng/L 
and  <4ng/L Others
0h cTnI 166ng/L 
or 30ng/L 
Sensitivity 93.3% 
NPV 98.6% 
AMI n=6 
Rule-out 
n=420 (65%) 
Observational zone
n=149 (23%) 
Rule-in 
n=80 (12%) 
Specificity 96.6% 
PPV 76.3% 
AMI n=61 
Prevalence of AMI 
14.8% (n=22) 
B = 1h Validation  
Derivation n=1110 
0h/2h cTnI<10ng/L Others  35.5ng/L 
Sensitivity 98.4% 
NPV 99.4% 
AMI n=3 
Rule-out 
n=485 (44%) 
Observational zone
n=470 (42%) 
Rule-in 
n=155(14%) 
Specificity 97.1% 
PPV 82.6% 
AMI n=128 
Prevalence of AMI 
11.9% (n=56) 
C = 2h Derivation  
Validation n=549 
0h/2h cTnI<10ng/L Others  35.5ng/L 
Sensitivity 94.5% 
NPV 98.8% 
AMI n=4 
Rule-out 
n=338 (62%) 
Observational zone
n=143 (26%) 
Rule-in 
n=68 (12%) 
Specificity 96.6% 
PPV 76.5% 
AMI n=52 
Prevalence of AMI 
11.9% (n=17) 
D = 2h Validation  
Fig. 2. 1 h-algorithm (A=derivation cohort, B= validation cohort) and 2 h-algorithm (C= derivation cohort, D= validation cohort) for diagnosis of AMI using sensitive cTnI in patients
presenting with acute chest pain. AMI: acute myocardial infarction, h = hour(s), NPV: negative predictive value, n = number, PPV: positive predictive value.
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AMI (overall n = 70) was cardiac arrhythmia (n = 22), myocarditis
(n = 11), acute heart failure (n = 8), unstable angina (n = 5), otherTable 3
Baseline characteristics of patients with an adjudicated diagnosis of AMI incorrectly ruled-out
Age Gender Time since
CPO
History of
CAD
ECG Hs-TnT (peak valu
in italics)
0
h
1
h
2
h
3–1
h
Derivation cohort
56 Male 5 h Yes LBBB (new) 37 38 c
78 Male 4 h No T-wave inversion 55 53 45
73 Male 5 h Yes ST-depression 33 32 28 c
76 Male 4 h Yes LBBB (known) 20 20 18 18
71 Male 14 ha Yes Normal 9 9 22
Validation cohort
84 Male 4 h No Normal 48 40 38
89 Female 8 h No ST-depression 25 27 25 34
83 Male 12 h Yes T-wave-inversion, Q waves 25 27 28 30b
79 Female 1 h Yes ST-depression 18 19 22 24
81 Male 13 ha No ST-depression 37 33 40
58 Male 8 h Yes Normal 24 24 25
76 Male 6 h Yes Normal 61 51 44
Adjudication was based on all information becoming available during the clinical work-up of
(but not s-cTnI) as described in detail in the Methods. AMI = acute myocardial infarction, UA
bundle branch block, AVNRT= atrioventricular nodal reentry tachycardia, hs-cTn = high-sen
a Peak chest pain within 0–12 h.
b cTn within 24–48 h.
c Later samples available with other assay.cardiac origin (n = 6), non-cardiac origin (n = 8), hypertensive crisis
(n = 4), pulmonary embolism (n = 2), Takotsubo cardiomyopathy
(n = 2), and unknown origin (n = 2).by the s-cTnI 1 h- or 2 h-algorithm.
e s-cTnI (peak value
in italics)
Clinical discharge
diagnosis
CABG performed
in-hospital
PTCA performed
in-hospital
2 0
h
1
h
2 h 3–12 h
2 2 NSTEMI No Yes
1 1 1 Non-cardiac No No
4 8 5 Unknown cause No No
4 3 6 4 Unknown cause No No
1 3 1 UA No Yes
6 5 Chronic CAD No No
7 9 6 NSTEMI No No
5 5 6 NSTEMI No No
5 5 5 AVNRT No No
5 5 NSTEMI No Yes
5 5 NSTEMI No Yes
6 5 chronic CAD No No
these patients including coronary angiography as well as serial measurements of hs-cTnT
= unstable angina, CAD = coronary artery disease, CPO = chest pain onset, LBBB = left
sitivity cardiac Troponin, s-cTnI = sensitive cardiac Troponin I, h = hour(s).
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When we applied the algorithms to the subpopulation of early pre-
senters (time since chest pain onset/maximum ≤ 3 h), a similar perfor-
mance was observed (NPV 98.6% (CI 96.5–99.6) and sensitivity 93.4%
(CI 84.0–98.2) as seen in the overall cohort for the 1 h-algorithm, and
for the 2 h-algorithm (NPV 99.2% (CI 97.0–99.9) and sensitivity 96%
(CI 86.3–99.5)).
3.6. Mortality at 30-days and 1-year
30-days and one-year survivalwere signiﬁcantly associatedwith the
categories “rule-out”, “observe” and “rule-in” for all three groups.
Cumulativemortality rates for the 1 h-algorithm according to these cat-
egories were 0.2%, 1.0% and 3.0% for 30 days and 1.6%, 4.0% and 9.3% for
one year (both p b 0.001 by log-rank test) (Fig. 3). One-year mortality
for the 2 h-algorithm was similar (1.8%, 4.7% and 8.1%; p b 0.001),
respectively. More detailed information is given in the online-only
Data supplement.
4. Discussion
Hype and uncertainty created by hs-cTn assays has distracted re-
searchers from appropriately studying the potential of sensitive cTn as-
says. As themajority of institutions in the United States andworld-wide
use sensitive, but not hs-cTn assays, we performed a large multicenter
study to derive and validate 1 h- and 2 h-algorithms for rule-out
and rule-in of AMI using a thoroughly-examined sensitive cTnI assay
[8,10,12-23].We found overall a similar performance of the 1 h sensitive
cTnI algorithm as recently described for the 1 h-hs-cTnT algo-
rithm [11,31] and the 1 h-hs-cTnI algorithm [32] indicating that
accurate rule-out and rule-in are feasible much more rapidly than sug-
gested in current AHA/ACC [4] or ESC [5] guidelines in many patients
also using sensitive cTn assays.
We report four major ﬁndings. First, the NPV for AMI in the “rule-
out” zone deﬁned only by sensitive cTnI levels at presentation and the
change within 1 h was around 99% (99.5% in the derivation cohort
and 98.6% in the validation cohort). The NPV with the 2 h-algorithm
was similar. These algorithms assigned about 50% of patients toFig. 3. Kaplan Meier-curves for the cumulative all-cause mortality. (A) At 30-days and (B) at on
out”, “observe” and “rule-in”. ED = emergency department.the “rule-out” zone. Although the achieved NPVs for the 1 h- and
2 h-algorithms were very high, it is important to highlight that they
should only be used clinically in conjunction with full clinical assess-
ment including patient history and exam, and the 12-lead ECG. Full clin-
ical assessment should then allow clinicians to further increase the NPV,
as ECG changes and other “red ﬂags” were present in the vast majority
of the patients incorrectly ruled-out by the use of the algorithm alone.
All adjudicated AMIs missed by the algorithm alone were small and
would also escape detection, even with late sampling, given the rather
high clinical decision limits used currently in clinical practice in many
institutions [33]. When applying these algorithms, it is important to re-
member that beyond AMI additional acute life-threatening diseases
causing chest pain such as acute aortic syndrome, pulmonary embolism,
and tension pneumothorax need to be ruled-out, before patients can be
considered for early discharge from the ED. Also, not all patients in
whom AMI and the other three acute life-threatening disorders are
ruled-out are necessarily ideal candidates for rapid discharge. Most pa-
tients with unstable angina, although at much lower risk for death as
compared to patients with AMI [5,11], still might beneﬁt from hospital-
ization. Some patients with unstable angina can only be detected using
imaging stress test for myocardial ischemia (with appropriate manage-
ment according to the test results) scheduled shortly after discharge
from the ED. Appropriate standard operating procedures in the ED/
chest pain unit need to be installed in order not to lose patients for nec-
essary outpatient follow-up examinations, even if patients present dur-
ing the night or weekend.
Second, the PPV for AMI in the “rule-in” zone was about 80% (81.6%
in the derivation cohort and 76.3% in the validation cohort) for the 1 h-
algorithm as well as for the 2-algorithm. Most of the patients in the
“rule-in” zone with diagnoses other than AMI had conditions that
often require coronary angiography for accurate diagnosis including
Takotsubo cardiomyopathy, myocarditis, heart failure, cardiac arrhyth-
mias, and unstable angina [4,5]. Therefore, the immediate clinical
consequence of being assigned to the “rule-in” zone would be urgent
coronary angiography, unless clinical assessmentwould indicate anoth-
er obvious condition associated with acute cardiomyocyte damage, for
example hypertensive crisis. The “rule-in” zone of the sensitive cTnI
1 h/2 h-algorithms is more precisely deﬁned as in the 2011 ESC
algorithm [5]. As the “rule-in” of AMI in patients with mild elevationse year according to the classiﬁcation provided by the sensitive cTnI 1 h-algorithm in “rule-
168 S. Druey et al. / International Journal of Cardiology 195 (2015) 163–170in cTn often is challenging for clinicians [5], it is a key advantage of these
1 h/2 h-algorithms to provide more detailed guidance for “rule-in”.
Third, the 1 h/2 h-algorithms overall assigned 70% of patients a def-
inite process (either rule-out or rule-in), with 30% of patients remaining
in the observational zone. Thereby, these algorithmswere evenmore ef-
fective in the early triage of acute chest pain patients than for example
the recently developed accelerated diagnostic protocol (ADP) combin-
ing the Thrombolysis in Myocardial Infarction Score with cTn or hs-
cTn levels at 0 h and 2 h [34-37] which, depending on the speciﬁc
biomarker used, assigned 10–40% of patients for rapid “rule-out”. This
difference is explained by mainly two aspects. First, the 1 h/2 h algo-
rithms take full advantage of the diagnostic information provided by
the sensitive cTnI levels and their early changes, while the ADPs use a
single cTn cut-off level. Second, the ADPs exclusively select patients
for “rule-out”, but do not provide guidance for “rule-in”.
Fourth, cumulative 30-days mortality was 0.2% in patients assigned
the “rule-out” zone, further documenting the safety of this approach
and the suitability of many of these patients for early discharge.
Our ﬁndings extend and corroborate recent pilot data obtained for
the hs-cTnT 1 h-algorithm [11]. Overall, the performances of the sensi-
tive cTnI 1 h/2 h-algorithms were similar to that for hs-cTnT (NPV
100%, 95% CI 98–100%; PPV 80%, 95% 78–82%) [11] and hs-cTnI. The
small differences seem well explained by the small differences in
study design, as the adjudication was based on a different hs-cTn
assay in this analysis, while late samples of the same hs-cTnT assay
were used in the hs-cTnT pilot study [11]. Thereby, our data extend
the concept of an 1 h-algorithm fromhs-cTnT also to the thoroughly val-
idated sensitive cTn assay [8,10,12-23]. This is of major clinical impor-
tance as this assay is already commonly used in the United States and
worldwide. The ﬁnding that very early diagnosis is feasible with sensi-
tive cTn assays and not only hs-cTn assays is supported also by the suc-
cessful use of another sensitive cTnI assay within a 2 h ADP [37]. The
algorithms derived from our data-driven approach include a very low
cut-off level and small changes in s-cTnI. To some extent the data-
driven approach derived from our analyses seems to be at odds with
the general recommendation of interpreting laboratory measurements
only in the range, in which the precision of the assay is high (usually
CV b 10%). However, our ﬁndings indicate that it seems to be safe to
also use cut-off levels at which the assays has a higher imprecision.
This aspect is not unique to this analysis, but appeared e.g., also when
deriving and validating the approach of excluding AMI with a single
measurement of a very low blood concentration of hs-cTn [38-41]. Al-
ternatively our ﬁndings may imply that the precision of the s-cTnI
assay may be higher than predicted from theoretical models [17,19].
We would suggest using the same pre-selection algorithm for the
possible clinical application of this s-cTnI-based algorithm, as was
used for the selection of the patient cohort for these analyses: First, to
obtain the 12-lead ECG and identify patients with signiﬁcant ST-
segment elevations and second, to exclude patients with terminal
kidney failure requiring chronic hemodialysis.
Two logistic details merit consideration. First, the investigated cTn
assay is run on a large analyzer in the central laboratory. Accordingly,
results of measurements performed at presentation will only be avail-
able to clinicians at about 1 h and results of measurements performed
at 1 h will only be available to clinicians at about 2 h. Therefore, the
availability of point-of-care cTn assays with similar sensitivity and pre-
cision as the investigated cTn assay would theoretically lead to even
shorter time to decision. Although none of the currently available
point-of-care cTn assays fulﬁlls this requirement, future assays may
well do so. Of course, possible 1 h- or 2 h-algorithms with new point-
of-care cTn assay would need to be thoroughly derived and validated
as was done for this sensitive cTn assay. Second, logistic challenges in
a busy ED may invariably introduce some variability in the timing of
the “1 h blood draw” or “2 h blood draw”. Two observations suggest
that this should still allow achieving a similar NPV as in this study.
First, this was a “real-life” study performed in busy EDs. Therefore, thevariability in timing of the blood samples in other EDs applying these
algorithms can be expected to be similar to those already present in
this study. Second, insights obtained from a large registry in Sweden
suggested that cTn release in AMI is near linear in the vast majority of
patients [30]. Accordingly, rule-out is at least safe with a blood draw
performed later than suggested by the algorithm. However, the blood
draw should not be performed earlier than suggested as cTn release is
a time-dependent phenomenon.
The optimal management of patients assigned to the observational
zone likely will be highly individualized as this group is very heteroge-
nous. It may include coronary angiography in patients with a high clin-
ical suspicion of AMI, coronary CT-angiography in patients with low-to-
intermediate likelihood for AMI, a third cTn sample at 3 or 6 h, or no fur-
ther immediate diagnostic testing when complete clinical evaluation
has established for example a clear non-ACS ﬁnal diagnosis such as
rapid atrial ﬁbrillation or hypertensive crisis [4,5].
The clinical as well as economic beneﬁt associated with the shorten-
ing of the time required for “rule-in” or “rule-out” of AMI in patients
presenting with acute chest pain to the ED can be expected to be sub-
stantial. The clinical beneﬁt may not be restricted to the patients with
AMI that are now detected and treated several hours earlier. It will
apply also to patients with disorders other than AMI that can be detect-
ed and treated earlier, because the work-up of the most important dif-
ferential diagnosis of acute chest pain (AMI) no longer interferes with
theirs. In addition, as overcrowding in the ED itself is associated with
worse patient outcome [1,2], anymeasure that contributes to amore ef-
fective use of resources in the ED and the associated reduction in over-
crowding can be expected to indirectly also improve patient outcomes.
The economic beneﬁt will be largely driven by more rapid rule-out, as
it affects 50% of the overall patient population with acute chest pain in
the ED.
Potential limitations of our study merit consideration. First, our
studywas conductedwith patients presenting to the EDwith symptoms
suggestive of AMI. Additional studies for example in patients presenting
to a general practitioner are required to learn whether this algorithm
would also be effective and safe in patients with much lower pretest
probability. Second, the data presentedwas obtained in an observation-
al diagnostic study in which the sensitive cTnI 1 h/2 h-algorithms were
compared against a centrally adjudicated ﬁnal diagnosis. Treating phy-
sicianswere blinded to the investigational sensitive cTnI results and pa-
tientswere notmanagedbased on these results. The results obtained for
the sensitive cTnI 1 h/2 h-algorithms now warrant applying them pro-
spectively for clinical decision-making in conjunction with all other
clinical information in an interventional trial. Third, this diagnostic
study required written informed consent. Therefore, invariably the
rate of enrollment was lower than in a recent registry [38]. Fourth, we
cannot comment on the performance of the diagnostic 1 h/2 h algo-
rithms in patients with terminal kidney failure requiring dialysis, since
such patients were excluded from our study. Fifth, we developed
these algorithms for one speciﬁc thoroughly validated sensitive cTnI
assay [8,10,12-23]. It is unknown, whether other sensitive cTn assays
would allow the development of similarly effective and accurate
algorithms. Therefore, the 1 h/2 h algorithms developed and validated
in this analysis apply only to one speciﬁc sensitive cTnI assay. As the di-
agnostic algorithms are assay-speciﬁc, each of the other sensitive cTn
assays will require derivation and validation using stringent methodol-
ogy as done in this study. Sixth, not all patients did have hs-cTnT
concentrations measured at 6 h. This “real-life” study recruited consec-
utive patients providingwritten informed consent. Obviously, the dura-
tion of blood sampling feasible in the individual patient is unknown at
presentation. In order to maximize the number of available late sam-
ples, two sets of cTn concentrations were available for the adjudication
in each patient: First, the cTn concentrations obtained by the clinical
team at the time points as deﬁned according to the standard operating
procedure of the respective ED/chest pain unit. These time points usual-
ly were 0 h and 3–6 h. In case of clinical uncertainty or a new chest pain
169S. Druey et al. / International Journal of Cardiology 195 (2015) 163–170episode, additional cTn levels were obtained at later time points.
Second, the hs-cTnT concentrations measured from the blood samples
obtained within this study at 0 h, 1 h, 2 h, 3 h, and in some patients at
6 h. The exact time from patient presentation to the last cTn concentra-
tion measured as well as the time from chest pain onset to the last cTn
concentrationsmeasured is shown in detail in Table 4 in the online-only
Data Supplement.
In conclusion, using a simple algorithmmaximizing the diagnostic in-
formation entailed in sensitive cTnI levels obtained at presentation and
after 1 h (or 2 h) allows one to safely rule-out or accurately rule-in of
AMI in up to 70% of patients. The very low mortality in the “rule-out”
group further supports that most of these patients are candidates for
rapid discharge. Additional interventional studies are warranted and
necessary to quantify exactly the medical and economic impact of the
clinical application of these early algorithms.Funding
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